Shortened hormone therapy with radiation for high-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a shorter course of hormone therapy (2 years) plus a new hormone drug (6 months) with radiation is as effective as longer treatment for high-risk prostate cancer that hasn't spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer that is high-risk or very high-risk (based on your PSA, Gleason score, and tumor stage).
- Your cancer has not spread beyond the prostate (no lymph node or distant spread on PSMA-PET and MRI scans).
- You are able to receive hormone therapy (ADT) for 2 years and a newer hormone drug (ARTA) for 6 months.
- You are generally well enough to go about your daily activities (ECOG score 0-2).
- You have not had prior prostate removal surgery or more than 3 months of hormone therapy before the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of hormone therapy (androgen deprivation therapy) for men with a certain type of prostate cancer that is considered high-risk. The goal is to see if a shorter treatment period can still control the cancer while reducing side effects.
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
This trial tests a shorter course of hormone therapy plus targeted radiation for prostate cancer that has spread to a few spots (oligometastatic). The goal is to see if less hormone therapy can still control the cancer effectively.
This trial studies a more sped-up radiation schedule for men with certain local prostate cancers, given together with hormone therapy. It aims to keep cancer control while possibly reducing treatment time and making care easier.
This trial tests whether a shorter course of hormone therapy (ADT) combined with radiation is as effective as the standard longer course for men with high-risk prostate cancer that has not spread. It aims to reduce side effects while keeping the cancer under control.
This study tests whether a shorter course of a newer hormone pill (apalutamide or enzalutamide) works well for men whose prostate cancer has spread to just a few spots and who recently started standard hormone therapy. It may allow you to take medication for less time while still controlling the cancer.
Hear when a new Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.